Methods to predict and lower the risk of prostate cancer.

Abstract

Chemoprevention for prostate cancer (PCa) continues to generate interest from both physicians and the patient population. The goal of chemoprevention is to stop the malignant transformation of prostate cells into cancer. Multiple studies on different substances ranging from supplements to medical therapy have been undertaken. Thus far, only the studies on 5 alpha-reductase inhibitors (the Prostate Cancer Prevention Trial [PCPT] and Reduction by Dutasteride of Prostate Cancer Events [REDUCE] trial) have demonstrated a reduction in the risk of PCa, while results from the Selenium and Vitamin E Cancer Prevention Trial (SELECT) concluded no decreased risk for PCa with selenium or vitamin E.

• Authors: Barbara Ercole, Dipen J Parekh
• Journal: TheScientificWorldJournal (ScientificWorldJournal) Vol. 11 Pg. 742-8 (Apr 05 2011) ISSN: 1537-744X [Electronic] United States
• PMID: 21479345 (Publication Type: Journal Article, Review)

Chemical References

• 5-alpha Reductase Inhibitors
• Vitamin E
• 3-Oxo-5-alpha-Steroid 4-Dehydrogenase
• Selenium

Topics

• 3-Oxo-5-alpha-Steroid 4-Dehydrogenase (drug effects)
• 5-alpha Reductase Inhibitors (administration & dosage)
• Chemoprevention
• Humans
• Male
• Prostatic Neoplasms (prevention & control)
• Risk Reduction Behavior
• Selenium (administration & dosage)
• Vitamin E (administration & dosage)